Most Clicked StoriesMore >


Pfizer to buy Medivation for $14B

BIO SmartBrief | Aug 22, 2016

Pfizer has completed negotiations to take over Medivation in a cash deal worth about $14 billion. The acquisition will give Pfizer access to Medivation's prostate cancer treatment, Xtandi, and late-stage assets. The Wall Street Journal (tiered subscription model) (08/22) Bloomberg (08/22)


FDA fast-tracks treatment for Alzheimer's from AstraZeneca, Lilly

BIO SmartBrief | Aug 23, 2016

DS Biopharma launches spinoff for fibrotic and pulmonary diseases

BIO SmartBrief | Aug 24, 2016

Pfizer's abuse-deterrent opioid painkiller wins FDA nod

BIO SmartBrief | Aug 22, 2016

Bayer, CRISPR form joint venture Casebia

BIO SmartBrief | Aug 22, 2016

F-star, Denali to collaborate on antibodies for CNS targets

BIO SmartBrief | Aug 26, 2016

BARDA awards contract to SAB Biotherapeutics for MERS-CoV drug development

BIO SmartBrief | Aug 25, 2016

BARDA to fund development of Regeneron's MERS treatment

BIO SmartBrief | Aug 23, 2016

Pfizer acquires small-molecule antibiotics from AstraZeneca

BIO SmartBrief | Aug 25, 2016

Ovarian cancer drug from Clovis gets FDA priority review

BIO SmartBrief | Aug 24, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Save on shipping with FedEx®

BIO SmartBrief | Aug 29, 2016

Registration is open for the 2016 BIO Latin America Conference

BIO SmartBrief | Aug 29, 2016

Don't miss the Animal Biotech Summit: Advancing One Health through biotechnology

BIO SmartBrief | Aug 26, 2016

Secure document sharing services optimized for life science

BIO SmartBrief | Aug 25, 2016

Big savings on lab supplies, equipment & chemicals

BIO SmartBrief | Aug 24, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more